The present disclosure relates to cultured adipose tissue. In one embodiment, the cultured adipose tissue is produced by culturing adipose cells in a culture media in vitro, harvesting the adipose cells after a desired amount of adipose cells are produced, and aggregating the harvested adipose cells to provide the cultured adipose tissue. In some embodiments, aggregating the harvested adipose cells comprises mixing the harvested adipose cells with a hydrogel or binder in a three-dimensional (3D) mold. In other embodiments, aggregating the harvested adipose cells comprises cross-linking the harvested adipose cells in a 3D mold. The cultured adipose tissue have a defined 3D shape and a size on the macroscale. In some embodiments, the cultured adipose tissue may be a food product.

An object of the present invention is to provide a method for producing insulin-producing cells having sufficient glucose responsiveness from mesenchymal stem cells, an insulin-producing cell having sufficient glucose responsiveness, a cell structure containing the insulin-producing cell, and a pharmaceutical composition. According to the present invention, there is provided a method for producing an insulin-producing cell from a mesenchymal stem cell, including (a) a step of producing a cell structure by incubating a plurality of biocompatible macromolecular blocks and a plurality of mesenchymal stem cells, and (b) a step of culturing one or more of the mesenchymal stem cells before the incubation in the step (a), the mesenchymal stem cell in the incubation in the step (a), or the cell structure produced in the step (a) in a medium containing the GLP-1 receptor agonist, and (c) a step of culturing the cell structure obtained in the step (a) or the step (b) in a medium containing the water-soluble vitamin and the hepatocyte growth factor.

Provided are mesenchymal stromal cell (MSC)-derived extracellular vesicles (EV) having tethered (membrane-bound) TGF- (MSC-derived membrane-tethered TGF- EV), and compositions containing such EV for use as therapeutics and immunomodulatory agents. Provided also are diagnostic methods and methods of assessing or monitoring disease status and/or progression in patients using membrane-tethered TGF- derived from a variety of cell sources that serve as detectable, quantifiable biomarkers in biological samples. The MSC-derived membrane-tethered TGF- EV can also be used to deliver various bioactive agents to a target cell or tissue for treating various diseases. The level of TGF- tethered to the membrane of the EV can also be modified or manipulated in vitro or ex vivo. Such modified MSC-derived membrane-tethered TGF- EV are useful as immunotherapeutic agents in the treatment or management of certain diseases, particularly those involving inflammation, autoimmunity, transplant rejection and cancer.

The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

The present invention provides compounds of formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

Provided are stem cells-induced Serotoli-like cells, methods of preparing the same, and uses thereof. Sertoli-like cells according to one embodiment can be differentiated from embryonic stem cells with excellent proliferative capacity, and thus, can be obtained in large quantities. Also, since the Sertoli-like cells secrete immunosuppressive substances and form immune privilege and induce anti-inflammatory functions, they can be used for development of the cell therapeutic agent.

The present invention comprises a culture medium composition for the proliferation and differentiation of mesenchymal stem cells into osteoblasts, the composition comprising a bone morphogenic protein (BMP) complex with TGF-f3, bFGF, VEGF, and IGF, bound to collagen type 1 dissolved into a mesenchymal stem cell culture medium. Methods of use of the composition and/or the BMP complex comprise: performing a diagnostic assay detecting a level of bone morphogenetic proteins in a patient serum level; determining if the BMP level is below a threshold level; and when the BMP level is below the threshold level, administering a composition comprising a BMP complex, with or without a pharmaceutical, such as a drug for treating and/or preventing osteoporosis. The present invention comprises performing an in vivo lavage and bone assay; and administering the BMP complex composition to a patient in need thereof.

The invention relates to implantable collagen devices made by seeding at least one elongate collagen construct, e.g., comprising at least one elongate synthetic collagen fiber with a plurality of cells and applying a strain and/or stress to the at least one elongate collagen fiber to induce the cells to differentiate into target phenotypes, e.g., tendon or ligament phenotype cells (and/or fibroblasts), typically with an extracellular matrix of collagen to organize into a tissue on the at least one collagen fiber.

A method of obtaining a pluripotent-like multipotent cell, including providing a cell of a first type which is not a pluripotent-like multipotent cell; contacting the cell of a first type with an agent capable of remodeling the chromatin and/or DNA of the cell; transiently increasing expression of at least one pluripotent gene regulator in the cell of a first type, to a level at which the at least one pluripotent gene regulator is capable of driving transformation of the cell of a first type into the pluripotent-like multipotent cell; and placing or maintaining the cell in a differentiation medium and maintaining intracellular levels of the at least one pluripotent gene regulator for a sufficient period of time to allow a stable pluripotent-like multipotent cell to be obtained; wherein the pluripotent-like multipotent cell so obtained does not exhibit teratoma formation in vivo.

The present invention relates to a method for the preparation of autologous human primary hair follicles in 3D cultures, comprising the isolation of primary fetal follicles; isolation of the patient's hair follicle cells; isolation of skin cells of the patient's scalp; extraction of growth factors from fetal follicle cells; the fibrin gel creation that contains growth factors of fetal follicles; sandwich cultivation of patient's hair follicle cells and skin of the patients scalp on or into fibrin gel that contains growth factors of fetal follicles; separation from fibrin gel the patients primary hair follicles, which can be used to treat baldness as an autologous graft.